Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 6, 1998, Pages 603-611

  Heiskanen, Tarja ^a   Olkkola, Klaus T ^a   Kalso, Eija ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; OXYCODONE; PLACEBO; QUINIDINE;

ADULT; ANALGESIA; ANTINOCICEPTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEMETHYLATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; LIVER METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

ADULT; ANALGESICS, OPIOID; COGNITION; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; OXYCODONE; PSYCHOMOTOR PERFORMANCE; QUINIDINE;

EID: 0032436459     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90051-0     Document Type: Article

References (38)

1. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47:639-46.
2. Kalso E, Pöyhiä R, Onnela P, Tigerstedt I, Linko K, Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991;35:642-6.
3. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 1993;11:973-8.
4. Ishida T, Oguri K, Yoshimura H. Determination of oxycodone metabolites in urines and feces of several mammalian species. J Pharmacobiodyn 1982;5:521-5.
5. Pöyhiä R, Kalso E, Seppälä T. Pharmacodynamic interactions of oxycodone and amitriptyline in healthy volunteers. Curr Ther Res 1992;51:739-49.
6. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
7. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer; II: comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978;207:101-8.
8. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991;48:2165-71.
9. Kaiko R, Benzinger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59:52-61.
10. Pöyhiä R, Olkkola KT, Seppälä T, Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 1991;32:516-8.
11. Weinstein SC, Gaylord JC. Determination of oxycodone in plasma and identification of a major metabolite. J Pharmacol Sci 1979;68:527-8.
12. Leow KP, Smith M. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration in rats. Life Sci 1994;54:1229-36.
13. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73:37-45.
14. Bäcklund M, Lindgren L, Kajimoto Y, Rosenberg P. Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 1997;9:30-35.
15. Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988;244:501-7.
16. Pöyhiä R, Kalso E. Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol Toxicol 1992;70:125-30.
17. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
18. Leemann T, Dayer P, Meyer UA. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 1986;29:739-41.
19. Brøsen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987;60:312-4.
20. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991;27:7-17.
21. Hannington-Kiff JG. Measurement of recovery from out-patient general anaesthesia with a simple ocular test. Br Med J 1970;3:132-5.
22. Stone BM. Pencil and paper tests: sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984;18:158-20.
23. Smith JM, Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects: a review. Psychopharmacologia 1976;47:175-82.
24. Cogan DG. Simplified entoptic pupillometer. Am J Ophthalmol 1941;24:1431-3.
25. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977;133:161-6.
26. Nielsen F, Rosholm JU, Brøsen K. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 1995;48:501-4.
27. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993;54:463-72.
28. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 1996;60: 295-307.
29. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996;42:747-56.
30. Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE, Fitzmartin RD. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage 1997;13:75-82.
31. Saarialho-Kere U, Mattila MJ, Paloheimo M, Seppälä T. Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol 1987;33:139-46.
32. Zacny JP, Lichtor JL, Klafta JM, Alessi R, Apfelbaum JL. The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers. Anesth Analg 1996;82:931-5.
33. Zhang Y, Britto M, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992;51:647-55.
34. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988;1:914-5.
35. Sindrup SH, Brøsen K, Bjerring P, Arendt-Nielsen L, Angelo HR, Larsen U, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not in poor metabolizers of sparteine. Clin Pharmacol Ther 1990;48:686-93.
36. Persson K, Sjöström S, Sigurdardottir I, Molnar V, Hammarlund-Udenaes M, Rane A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br J Clin Pharmacol 1995;39:182-6.
37. Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brøsen K, Nielsen F, et al. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 1996;49:503-9.
38. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effects of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.